Simple tricks to boost your immune system during coronavirus may help reduce the severity of the disease.
Turmeric or curcumin is being advocated by some medical experts for reducing lung inflammation in the backdrop of rising Covid-19 cases in India, which is especially known to attack the respiratory system. Turmeric is being touted as the only way to keep inflammation in your body low so that you have a better chance of fighting the coronavirus infection. In view of the current Covid-19 epidemic and the panic around it, medical experts have a few suggestions besides washing hands, not being in crowded spaces, etc., on how to boost the immune system and possibly minimize the symptoms as there are no cures for the disease. Vaccines are at least two years away and there are no drugs on the horizon except Actemra which is a biological drug that Roche had developed for arthritis. Simple tricks to boost your immune system during coronavirus may help reduce the severity of the disease. One major thing that happens when you get infected is that one has a “cytokine storm” in the body. Bad cytokines/hormones especially IL-6 and TNF-a levels rise which contribute to stress and organ failure during Covid-19 infection. The pharmaceutical company Roche has dusted off an old drug, Actemra, which was developed for arthritis as it was shown to suppress IL-6. Tocilizumab (Actemra) is in a class of drugs called biologics. Tocilizumab is a treatment for adults with moderate to severe rheumatoid arthritis (RA), giant cell arthritis, and polyarticular and systemic juvenile idiopathic arthritis. Even if this drug is approved for Covid-19, it will cost at least $25,000-30,000 per patient. Nature has effective molecules for lowering IL-6 naturally: Turmeric/curcumin, Resveratrol, and Lutein. Turmeric/curcumin is especially excellent in reducing lung inflammation. This is the only way to keep inflammation in the body low so that one has a better chance of fighting off this infection. Issued in Public Interest by Bagdara Farms
Best estimates for Corona (COVID19) is 10 times more lethal than seasonal flu.
Critically important studies emerging from China suggest that for many patients who die of Covid-19, it may be their own immune system, rather than the virus itself, that deals the fatal blow. This is called a cytokine storm. During a cytokine storm, an excessive immune response ravages healthy lung tissue, leading to acute respiratory distress and multi-organ failure. Untreated, cytokine storm syndrome is usually fatal. Patients in other studies who developed cytokine storm syndrome after viral triggers often ironically possessed subtle genetic immune defects resulting in the uncontrolled immune response. Over the past two decades, much has been learned about the diagnosis and treatment of cytokine storm syndromes. On the front lines of the Covid-19 response, it is critical that medical professionals are aware of the syndrome and prepared to identify and treat it. This act of preparation could help to significantly reduce the number of deaths from Covid-19. In treating cytokine storms brought about by other illnesses, like other viral infections and autoimmune diseases, death rates among patients suffering a cytokine storm have been reduced to as low as 27 percent. Until vaccines for the novel coronavirus are available, likely a year or more from now, it is possible that millions of people may become infected around the globe. This is in part due to minimal early symptoms in up to 80 percent of those who become infected. However, seemingly mild cases of Covid-19 can morph into more severe cases involving the lower lungs, and up to 20 percent of symptomatic novel coronavirus infected individuals require hospitalization, with 5 percent overall needing intensive care. Although individuals who are elderly or who have underlying chronic health problems are at a higher risk of mortality, younger previously healthy people have also succumbed to severe Covid-19 Cytokine storm syndromes go by many names, but they share the pathology of an overly active immune response that leads to frequently fatal multi-organ dysfunction syndrome (MODS). The risk factors for why some previously healthy individuals become deathly ill remain unknown. There are likely host factors, including genetic mutations that put individuals at higher risk. Until the risk factors are known, the medical community will need to treat those Covid-19 patients based solely on the severity of their disease. How to screen for cytokine storm syndrome in sick patients While novel and repurposed anti-viral therapies are being explored to treat Covid-19, those individuals with cytokine storm syndrome also require treatment of the overly active immune response. In these situations, an overactive immune response can be deadly. All Covid-19 patients sick enough for hospitalization should be given a cheap, quick, and readily available serum ferritin blood test. Indeed, elevated serum ferritin values have recently been reported in Chinese hospitalized patients with Covid-19. This is a good first screening tool for the possibility of a cytokine storm syndrome in sick patients with high fevers. The question then remains how best to treat a cytokine storm syndrome once it is identified. The treating physician is often placed between a rock and a hard place. Corticosteroids can be powerfully broad immunosuppressive agents, and they are inexpensive and readily available throughout the world. However, it can be frightening for a physician to treat a severely ill, infected individual with such powerful and wide-ranging immune suppression. We already have medicines for treating cytokine storm syndrome triggered by viruses With the development of biologic therapies for a variety of rheumatic, oncologic, and other conditions, novel approaches to treating the immune response are now available. These highly-targeted medicines go after one or a few inflammatory molecules, including cytokines, without the general immune suppression affected by corticosteroids and other relatively non-selective immune suppressants. Recently, a number of specific anti-cytokine approaches have proven effective in treating a variety of cytokine storm syndromes, including those triggered by viruses. These include drugs targeting interleukin-1 (IL-1), IL-6, IL-18, and interferon-gamma. While randomized trials will be needed to confirm which, if any, of these therapeutics will effectively treat Covid-19-infected patients with cytokine storm syndrome, IL-6 blockade has recently been reported to be in use in China with successful outcomes in some individuals receiving this as part of their treatment. While working to prevent future outbreaks of deadly coronavirus infections with vaccine development and discovering new or re-purposed anti-viral medicines to treat the virus, we must also use all the knowledge at our disposal to treat those patients most at risk of dying – including from Covid-19-induced cytokine storms. For this to occur, the medical community must first be aware of the possibility, then make the diagnosis, and finally treat infected individuals with overly active immune responses that are harmful, if not fatal, left untreated. This should help save the lives of those unfortunate individuals at risk of Covid-19 induced cytokine storm syndrome. Randy Q. Cron, MD, Ph.D., is a professor of pediatrics and medicine and director of the Division of Pediatric Rheumatology at the University of Alabama at Birmingham. In November 2019, he published Cytokine Storm Syndrome, the first dedicated textbook on cytokine storms. Winn Chatham, MD, is a professor of medicine, clinical immunology, and rheumatology; senior scientist at the Comprehensive Arthritis, Musculoskeletal, Bone and Autoimmunity Center (CAMBAC); and director of Rheumatology Clinical Services at the University of Alabama at Birmingham The use of curcumin should be investigated in patients with severe flu symptoms and cytokine storm. Curcumin blocks cytokine release, most importantly the key pro-inflammatory cytokines, interleukin-1, interleukin-6, and tumor necrosis factor-α. The suppression of cytokine release by curcumin correlates with clinical improvement in experimental models of disease conditions where a cytokine storm plays a significant role in mortality.
Anti-infective Properties of the Golden Spice Curcumin
The search for novel anti-infectives is one of the most important challenges in natural product research, as diseases caused by bacteria, viruses, and fungi are influencing the human society all over the world. Natural compounds are a continuing source of novel anti-infectives. Accordingly, curcumin has been used for centuries in Asian traditional medicine to treat various disorders. Numerous studies have shown that curcumin possesses a wide spectrum of biological and pharmacological properties, acting, for example, as an anti-inflammatory, anti-angiogenic, and anti-neoplastic, while no toxicity is associated with the compound. Recently, curcumin’s antiviral and antibacterial activity was investigated, and it was shown to act against various important human pathogens like the influenza virus, hepatitis C virus, HIV, and strains of Staphylococcus, Streptococcus, and Pseudomonas. This review summarizes the current knowledge and future perspectives of the antiviral, antibacterial, and antifungal effects of curcumin. Infectious diseases are ailments caused by pathogenic viruses and microorganisms such as bacteria and fungi. Infections can spread directly from person to person and from animal to human, or indirectly via contaminated water and food. This can result in small local outbreaks and epidemics, like the plague, syphilis, and SARS, or pandemics affecting several countries, of which the flu is one of the best-known examples. In times of globalization and climate change, infectious diseases are spreading more rapidly than ever before, and new ones continue to emerge. Even though they are a global health burden, inhabitants of developing countries especially suffer from infections. Accordingly in 2010, worldwide, roughly one-quarter of deaths were due to infectious diseases, while in low-income countries, nearly 60% of fatalities could be attributed to them (Dye, 2015). This is primarily because in these regions often hygienic measures are insufficient, diagnostic tools are lacking and therapeutic options are not available. Existing medications are categorized into antivirals used to combat viral diseases, antibiotics contradicting bacterial infections, and antifungals inhibiting the growth of fungi. In addition, multiple vaccines preventing viral and bacterial diseases exist, which has already led to the successful eradication of smallpox. However, countermeasures are available only for a limited number of pathogens, not including all potentially lethal and pandemic agents, as e.g., Ebola virus and resistance to current therapies are increasing. Thus, new therapeutic options are urgently needed. Natural compounds are a continuing source of new drugs. From 1940 to 2 014, 49% of all small molecules approved by the US Food and Drug Administration (FDA) were natural products or derivates directly linked to them (Newman and Cragg, 2016). One plant that has been extensively studied on that score is turmeric. Turmeric (Curcuma longa L.) belongs to the family of ginger (Zingiberaceae) and natively grows in India and Southeast Asia. The plant’s rhizomes contain several secondary metabolites including curcuminoids, sesquiterpenes, and steroids (Omosa et al., 2017); with the curcuminoid curcumin being the principal component of the yellow pigment and the major bioactive substance. Chemically, curcumin is a diferuloylmethane, a diarylheptanoid belonging to the class of natural phenols. Its chemical structure has been described already in 1910 as a symmetric molecule of two phenol rings connected by α,β-unsaturated carbonyl groups(Miłobȩdzka et al., 1910). The use of curcumin is not associated with toxicity, and the FDA categorized it as “Generally Recognized As Safe.” Thus, the medical properties of natural products have been widely investigated. Today, a literature search at pubmed.gov finds over 11,000 publications, while a quest at clinicaltrials.gov reveals 179 clinical studies using curcumin. Most studies analyzed curcumin’s anti-cancer effect and it has been shown to inhibit tumor cell proliferation, invasion, and metastatic dissemination (as reviewed, e.g., Bachmeier et al., 2018). Besides this, curcumin has been documented to act, e.g., anti-inflammatory and anti-infective (as reviewed, e.g., Hatcher et al., 2008) and due to its wide spectrum of biological and pharmacological properties it is often called “cure-cumin.” For curcumin, an antiviral activity was observed against several different viruses including hepatitis viruses, influenza viruses, and emerging arboviruses like the Zika virus (ZIKV) or chikungunya virus (CHIKV). Interestingly, it has also been reported that the molecule inhibits human immunodeficiency virus (HIV), herpes simplex virus 2 (HSV-2), and human papillomavirus (HPV), indicating that curcumin reduces the spread of sexually transmitted diseases. Curcumin Inhibits Human Immunodeficiency Virus Curcumin Inhibits Hepatitis Viruses Curcumin Inhibits Influenza A Virus Curcumin Inhibits Herpesviruses Curcumin Inhibits Human Papillomavirus Curcumin Inhibits Respiratory Syncytial Virus Curcumin Inhibits Noroviruses Curcumin Inhibits Arboviruses More details of this can be found directly at US National Library of Medicine National Institutes of Health https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6509173/ You can order a bottle of Turmflu from our website https://bagdarafarms.com/product/turmflu/ or you can call our IVR @ 9560254646
The use of curcumin should be investigated in patients with Severe Viral Infections like Corona (COVID-19)
Curcumin Suppression of Cytokine Release and Cytokine Storm. Potential Therapy for Patients with Ebola and Other Severe Viral Infections (Reference: http://iv.iiarjournals.org/content/29/1/1.full#sec-3) Background: The terminal stage of Ebola and other viral diseases is often the onset of a cytokine storm, the massive overproduction of cytokines by the body’s immune system. Materials and Methods: The actions of curcumin in suppressing cytokine release and cytokine storm are discussed. Results: Curcumin blocks cytokine release, most importantly the key pro-inflammatory cytokines, interleukin-1, interleukin-6, and tumor necrosis factor-α. The suppression of cytokine release by curcumin correlates with clinical improvement in experimental models of disease conditions where a cytokine storm plays a significant role in mortality. Conclusion: The use of curcumin should be investigated in patients with Severe Viral Infections like Corona (COVID-19). Our self cultivated, harvested, processed, and distributed curcumin enriched whole room Curcuma longa powder can help keep your families and friends safe and healthy. We Recommend Turmflu for the current concern of COVID-19. It can be ordered from our website https://bagdarafarms.com/product/turmflu/
Here are some of the existing drugs that may be repurposed to treat coronavirus
Here are some of the existing drugs that may be repurposed to treat coronavirus Pharmaceutical companies and research facilities are looking at a variety of existing drugs as treatment options for COVID-19. Here’s a partial list. Pharmaceutical companies and research facilities are working to find new, successful treatments for those infected with the coronavirus. But clinical trials and FDA approval can take time, so while new drugs are being developed, companies are seeing if older drugs can be repurposed. Here’s a list of some of the options being explored and why they might be useful in blunting the effects of coronavirus. Actemra and other rheumatoid arthritis drugs Doctors in China have used an anti-inflammation drug to curb the effects of the coronavirus on critical patients, and now the maker of the drug says it is talking to the Food and Drug Administration about clinical trials. Tocilizumab, sold under the name Actemra and made by the Swiss pharmaceutical firm Roche, is a prescription medicine used to treat adults with moderate to severe active rheumatoid arthritis, as well as certain types of juvenile arthritis. Chinese doctors have used Tocilizumab to prevent an overreaction of the immune system that has led to organ failure and death in coronavirus patients. An initial clinical trial in China used Actemra in 20 severe COVID-19 cases. Nineteen of the patients were discharged from the hospital within two weeks and one got better, according to China’s National Health Commission. The drug has now been approved for use in China but has not yet been approved in the United States. Karsten Kleine, a spokesperson for Roche, told NBC News that the drug company “is in active discussions with the FDA, as well as government bodies and institutions around the world, to initiate clinical trials that evaluate the safety and efficacy of Actemra (tocilizumab) for the treatment of severely ill COVID-19 patients.” Roche is not alone in looking into rheumatoid arthritis drugs as a potential treatment. Sanofi and Regeneron are launching a clinical trial in New York to see if their rheumatoid arthritis drug Kevzara is effective. HIV drugs AbbVie, the creator of HIV drugs Kaletra/Aluvia, is collaborating with health authorities to determine the efficacy of using its HIV drugs to treat COVID-19. The company is working with the FDA, CDC, and European agencies to set up clinical trials of the drug. At this time, AbbVie told NBC News it cannot confirm Chinese media reports that the drug has been successful in treatment as it does not have access to Chinese clinical information. It is monitoring its current supply to make sure current HIV patients being treated by the drug will not be affected by an increase in demand. Malaria drugs Sanofi is assessing the risk and benefit of its malaria drug hydroxychloroquine for the management of coronavirus. According to the company, some health authorities are allowing the temporary use of chloroquine for the management of COVID-19, but there is insufficient data to draw any conclusions over its efficacy. Any use of the drug in this context is considered “off-label” use. Based on encouraging preliminary findings from a study in France, Sanofi is looking at ways to collaborate and partner with health authorities investigating the use of hydroxychloroquine for the management of coronavirus. Remdesivir Remdesivir is a broad spectrum anti-viral medication developed by Gilead Sciences as a treatment for Ebola and also showed success in the treatment of monkeys infected with MERs, a different type of coronavirus. It is now being tested as a potential COVID-19 treatment. Almost all these pharmacological actions of different drugs shortlisted in the COVID-19 treatment protocol globally are also shown by Curcumin found in Turmeric. China has been promoting its herbal treatment for treating symptoms of Corona. Please choose a natural response to a nature’s problem. We recommend our product Turmflu for yourself and your family and this can be ordered from our website https://bagdarafarms.com/product/turmflu/ As our contribution, we are giving away 1 Free Bottle on every order of 2 Bottles of Turmflu. Stay Safe.